NRG
INSM icon

Nemes Rush Group’s Insmed INSM Stock Holding History

Nemes Rush Group’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$327 Sell
2
-2
-50% -$307 ﹤0.01% 905
2025
Q4 		$696 Buy
+4
New +$730 ﹤0.01% 851
2025
Q3 		– Sell
-3
Closed -$302 – 710
2025
Q2 		$302 Buy
+3
New +$229 ﹤0.01% 702

Other funds holding INSM

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Nemes Rush Group's INSM Position: Q1 2026 in Review

Nemes Rush Group reduced its Insmed (INSM) stake by 50% in Q1 2026, selling an estimated $307 and leaving 2 shares worth $327. The position accounts for ﹤0.01% of the portfolio, ranked #905.

Nemes Rush Group first reported a position in INSM in Q2 2025 and has held it in 3 quarters since. The position peaked at $696 in Q4 2025. 670 funds tracked by Wall St. Rank hold INSM as of Q1 2026.

  • Nemes Rush Group held 2 shares of Insmed worth $327 as of Q1 2026.
  • Nemes Rush Group sold 2 Insmed shares in Q1 2026, an estimated $307.
  • Insmed made up ﹤0.01% of Nemes Rush Group's portfolio in Q1 2026, its #905 holding.
  • Nemes Rush Group first reported a position in Insmed in Q2 2025 and has held it in 3 quarters since.
  • Nemes Rush Group's Insmed position peaked at $696 in Q4 2025.
  • 670 funds tracked by Wall St. Rank held Insmed as of Q1 2026.

Based on Nemes Rush Group's 13F filing for Q1 2026, filed 21 Apr 2026.